#1614 Another SLR informing the 2025 EULAR recommendations for PMR & LVV 🧭 Fast-track clinics cut blindness & diagnostic delays; multimodal imaging pathways outperform biopsy alone. Key data shaping future referral & diagnosis guidance. @RheumNow #ACR25

What is better in #PsA post #TNFi? #RCT of #secukinumab v #ustekinumab The big 🤔? #IL17Ai vs IL12/23i 🏆 #Cosentyx ✈️✅PASI ⚜️✅ACR50 Will H2H studies change our #prescribing?🤷‍♀️ #rheums Rx #IL17i>#IL12i/23i vs #derms #ACRBest #ACR25 @RheumNow @ACRheum abst#LB06 https://t.co/RpC8ymDc7H

• https://x.com/Janetbirdope/status/1982822570379325563/photo/1

#ACR25 Abstr#1525 Find me at poster hall. Super-responders exist with rituximab, not just confined to CAR-T! Our cohort study = 23/114 (20%) had resp duration >3-yrs; 15/23 were IS-Free. Poor prognostics (Non-White, APS) & shorter #SLE duration predicted super-tesponse @RheumNow https://t.co/nJQFmiIj2n

• https://x.com/Yuz6Yusof/status/1982822156774846648/photo/1
• https://x.com/Yuz6Yusof/status/1982822156774846648/photo/1

To #cycle within or go to another drug class I #axSpA? #RCT of #TNFi-IR 👇 2nd #TNFi v #IL17i #IJDM it doesn’t matter what choice as #IL17i WAS NOT superior to TNFi cycling from 1st -2nd 👍 stay in #TNFi class = change to #IL17i #ACR25 @RheumNow abst#LB09 #ACRBest @ACRheum https://t.co/VCdL5CUYUa

• https://x.com/Janetbirdope/status/1982822671504085337/photo/1
• https://x.com/Janetbirdope/status/1982822671504085337/photo/1

The CLASSIC study validated the performance of the 2009 ASAS classification criteria Model A was chosen for the revised criteria since it achieved prespecified performance targets of SN ≥75% and SP ≥90% 🔸Pso was included 🔸⬆️CRP replaced dactylitis #ACR25 @RheumNow Abs0854 https://t.co/tK52rQyaRa

• https://x.com/RHEUMarampa/status/1982822937364238726/photo/1
• https://x.com/RHEUMarampa/status/1982822937364238726/photo/1
• https://x.com/RHEUMarampa/status/1982822937364238726/photo/1

🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/xn4yUta9Da

In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b

• https://x.com/synovialjoints/status/1982798184226156627/photo/1

Time for the 2nd plenary session! 🎤 #0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients. Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP

• https://x.com/DrMiniDey/status/1982796925377388991/photo/1

This morning in the plenary, same theme, but in PsA: Similar metabolic/CV concerns Similarly benefit from GLP-1 RA looking at TriNetX data again, reduced MACE Now prospective trials in rheum disease, for both metabolic benefits & disease activity? #ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG

• https://x.com/drdavidliew/status/1982796177725591741/photo/1

GLP-1 RA meds: we are just starting to see their impact in rheumatoid arthritis. We know metabolic, CV risk in RA, but what to do? RA pts in TriNetX, obese non-diabetic GLP-1 RA reduced 1y CV events & also all-cause mortality Soon will be near-standard #ACR25 ABST0445 @RheumNow https://t.co/4ptAHdmf9q

• https://x.com/drdavidliew/status/1982794776119226821/photo/1

Key slide and takeaways on the ACR 2025 extrarenal SLE guideline. Presented by Lisa Sammaritano @RheumNow #ACR25 #ACRBest https://t.co/Xa97O6RdBY

• https://x.com/synovialjoints/status/1982786862788817112/photo/1